Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — H1 2026 Earnings Presentation
33 slides from Nxera Pharma's earnings presentation, Aug 7, 2026
Slide 1: H1 FY2026 Financial Results
EXTERNAL NON-CONFIDENTIAL H1 FY2026 Financial Results 6-month period ended June 30, 2026 7 August 2026 | Nxera Pharma Co., Ltd. (TSE: 4565)
Slide 2: Disclaimer
The material that follows is a presentation of general background information about Nxera Pharma Co., Ltd and its subsidiaries (collectively, the “Company”) as of the date of this Disclaimer presentation. This material has been prepared solely for informational purposes and is not to be construed as
Slide 3: Agenda
Agenda 01 Operational Highlights 02 Financial Results 03 Japan / APAC Commercial 04 UK R&D 05 The Road Ahead 06 Q&A 3
Slide 4: Operational Highlights
Operational Highlights Chris Cargill, President and CEO 01
Slide 5: H1 Operational Progress – moving rapidly from investment to delivery
H1 Operational Progress – moving rapidly from investment to delivery FINANCIAL PERFORMANCE COMMERCIAL BUSINESS PLATFORM BUSINESS REVENUE (JPY M) PIVLAZ® SALES 18,910 MULTIPLE REVENUE-GENERATING MILESTONES ACHIEVED 15,094 ¥ 6,334M $23M $20M (+9.1% YOY) $2M $3M $4M Undisc. H1 2025 H1 2026 OPERATING
Slide 6: Priority objectives for FY2026
Priority objectives JPY 19.5 billion+ Net product sales JPY 9.9 billion for FY2026 01 (PIVLAZ® plus QUVIVIQ®) Progress: 51% Commercial Get one or more late-stage assets Multiple ongoing 02 for Japan and APAC (excl. China) discussions Commercial Sign one or more high-value Active term sheet 03 partne
Slide 7: Financial Results
Financial Results Hironoshin Nomura, CFO 02
Slide 8: Key financial results (H1 FY2026)
Key financial results (H1 FY2026) Achieved profitability in both core OP and OP (JPY million) PROGRESS IN H1 FY2026 25,000 ◼ Received multiple milestone payments from Neurocrine, 20,000 18,910 Centessa, Lilly, AbbVie, and Platform 921 others 15,094 ◼ Initiation of Phase 2 trial of 15,000 1,053 M1/M4
Slide 9: Breakdown of H1 financial results (FY2026)
Breakdown of H1 financial results (FY2026) Both our commercial and platform businesses are now profitable Consolidated Consolidated (JPY million) Platform*1 ＋ Commercial*2 = P&L (Core) ＋Non-core costs = P&L (IFRS) (YoY) (YoY) (YoY) (YoY) Revenue 8,945 +46% 9,965 +11% 18,910 +25% Total: 4,613 18,910
Slide 10: Japan/APAC Commercial
Japan/APAC Commercial Toshi Maeda, COO and President of Nxera Pharma Japan 03
Slide 11: PIVLAZ®
PIVLAZ® (clazosentan, an endothelin A antagonist) Commercial Our first commercially available product for the prevention of cerebral vasospasm in patients with Aneurysmal Subarachnoid Haemorrhage (aSAH) PIVLAZ® quarterly sales PIVLAZ ® Annual Sales and Growth Rate Net Sales Market Share(patient base
Slide 12: QUVIVIQ®
QUVIVIQ® (daridorexant, dual orexin antagonist “DORA”) Commercial DORA is rapidly establishing its position in the treatment paradigm for insomnia Domestic Market Size for DORA QUVIVIQ® Annual Sales and Growth Rate (Bn JPY) 90 45% Daridorexant (Quviviq) 83 billion yen Suvorexant (Belsomra) 80 Lembor
Slide 13: Vamorolone (AGAMREE®) addresses the need for a tolerable steroid
Vamorolone (AGAMREE®) addresses the need for a tolerable steroid Commercial Compared with conventional corticosteroid therapy, the risk of treatment-related adverse events is reduced • Vamorolone confronts the limitations of standard Analyst consensus forecast of vamorolone in other countries cortic
Slide 14: UK R&D
UK R&D Patrik Foerch, CSO and President of Nxera Pharma UK 04
Slide 15: Achieved multiple milestones from discovery stage through to regulatory progress
Achieved multiple milestones from discovery stage through to regulatory progress Platform DISCOVERY PHASE 1 & PHASE 2 PHASE 3 & REGULATORY MILESTONE US$20M development $ Undisclosed US$1.8M & US$3M US$3.6M milestone Nxera in-licenses Japan QUVIVIQ® (daridorexant) milestone payment development milest
Slide 16: Three clinical-stage programs, with a plan to transition to new partners
Three clinical-stage programs, with a plan to transition to new partners Platform EP4 ag. GPR52 ag. EP4 ant. Inflammatory Bowel Disease Schizophrenia Cancer immunotherapy NXE’744 Phase 2-ready NXE’149 Phase 2-ready NXE’732 Phase 2a ongoing ✓ Phase1 completed ✓ Phase1 completed ✓ Mechanistic proof-of
Slide 17: Developing next-generation therapies for obesity, metabolic disorders, and endocrine diseases
Developing next-generation therapies for obesity, metabolic disorders, and endocrine diseases Platform Differentiation through an oral formulation and a novel binding mode in an obesity market dominated by injectables Obesity Market Opportunity and Our Development Program Differentiation & Developme
Slide 18: The road ahead
The road ahead – moving from investment to delivery Chris Cargill, President and CEO 05
Slide 19: Four value engines, each independently substantial, compounding together at pace
Four value engines, each independently substantial, compounding together at pace PRODUCTS Profitable and growing commercial platform in Japan 2030 TARGET: JPY40-50bn sales, >30% OP margin, 5 products NxWave® (StaR® SBDD) NxAQ® (AI/ML/QM) PLATFORM PRODUCTS NxAQ® & NxWave® PLATFORMS AI & quantum-level
Slide 20: Specialty and rare disease commercial platform
PRODUCTS Specialty and rare disease commercial platform – more than doubled top-line sales since 2023 REVENUE TRAJECTORY (JPY M) SINCE ACQUISITION (JULY 2023) ¥40,000-50,000 Revenue scaled 2.6x ¥19,500 ¥7,540 Costs removed 20% FY2022A (AT ACQUISITION) FY2026E FY2030E Profitable and cash generative P
Slide 21: Plan to extend AGAMREE® beyond DMD
PRODUCTS Plan to extend AGAMREE® (vamorolone) beyond DMD to three additional rare diseases INDICATION OVERVIEW PATIENT POPULATION CURRENT STANDARD THERAPY FUKUYAMA CONGENITAL Rare inherited muscle-wasting MUSCULAR DYSTROPHY • 1,000–2,000 patients • Symptomatic treatment only disease, almost only in
Slide 22: Meet the starting five
NxAQ® PLATFORM Meet the starting five building Japan’s global AI drug-discovery champion BEN ANNA ŽYGIMANTAS PETER WANLING TEHAN GAULTON JOČYS IBRAHIM SONG Computational Data AI/ML Platform Computational Sciences Science Research Engineering Engineering PROVEN DRUG HUNTERS, UNLOCKING FIFTEEN YEARS O
Slide 23: NxAQ® turns a compounding proprietary data asset
NxAQ® PLATFORM NxAQ® turns a compounding proprietary data asset into faster, higher-quality programmes A COMPOUNDING ASSET PROPRIETARY NxAQ® DISCOVERY PROGRAMME GPCR DATA PLATFORM DECISIONS 15 years of proprietary StaR® data: 493 GPCR structures, 59 receptors, 30,000 mutation datapoints, 400+ entiti
Slide 24: NxAQ® compresses timelines and costs
NxAQ® PLATFORM NxAQ® compresses timelines and costs to enable scalable GPCR drug design EVERY PROGRAM FEEDS THE DATASET REGULATED TIMELINES TARGET-TO-HIT HIT-TO-LEAD LEAD IND-ENABLING PHASE I SUBMISSION STUDIES PHASE II PHASE III OPTIMIZATION TO LAUNCH DEVELOPMENT CANDIDATE (DC) TRADITIONAL NxAQ® AV
Slide 25: Future obesity therapies will compete on more than weight loss
PIPELINE Future obesity therapies will compete on more than weight loss 1. GREATER EFFICACY 2. BETTER LOSS QUALITY 3. ACCESS & ADHERENCE 4. GREATER TOLERABILITY APPETITE + ENERGY BURN Cut fat & inflammation ORAL SMALL MOLECULES GENTLER LOSS GRADIENT SELECTIVE AMYLIN / Triple+ pharmacology, APCs PRES
Slide 26: Building a next-gen metabolic/rare disease biotech pipeline
PIPELINE Building a next-gen metabolic/rare disease biotech pipeline powered by NxAQ® and NxWave® 2026 DISCOVERY PIPELINE 2028 CLINICAL PIPELINE New Targets GLP-1 ag. New Targets PTH ag. GIPR Phase 1 New Targets DISCOVERY ASSETS Phase 1 Phase 2 New Targets TSH NAM Amylin ag. Phase 1 New Targets Undi
Slide 27: Three principal partnerships carry over US$4.5bn
PARTNERS Three principal partnerships carry over US$4.5bn of headline economics plus royalties HEADLINE ECONOMICS PROGRAMS OVERVIEW Direclidine (Schizophrenia) Ph 3 $2.6B + Muscarinic agonists H2’27 Direclidine (Bipolar), NBI-570 (Schiz.) Ph 2 Neuropsychiatry M4 Phase 3 Tiered Royalties data readout
Slide 28: Four value engines, each independently substantial, compounding together at pace
Four value engines, each independently substantial, compounding together at pace NEXT MAJOR MILESTONE EXPECTED PRODUCTS H2 2026: New in-licensed product(s) for Japan Profitable and growing commercial platform in Japan H2 2027: Filing for approval of vamorolone in Japan 2030 TARGET: JPY40-50bn sales,
Slide 29: Nxera
aA 29 Nxera:™
Slide 30: 2030 Vision
2030 Vision At least 5 products* Best-in-class, At least JPY50 Operating profit launched in Japan highest-potential billion in annual margin >30% opportunities revenues Revenue targets (JPY billion) Operating profit margin targets (%) Obesity, Metabolism, Endocrinology 80% 50.0 Opportunistic TAs (Ra
Slide 31: Multiple potential catalysts ahead in 2026
Multiple potential catalysts ahead in 2026* ✓ ：Completed PROGRAM PARTNER TIMING EVENT ✓ ORX142 (OX2 agonist) Feb 2026 Phase 2 study start ✓ ORX489 (OX2 agonist) Mar 2026 Phase 1 study start ✓ NBI’570 (M1/M4 ago) April 2026 Phase 2 study start ✓ Multiple discovery collaboration progress 1H 2026 Progr
Slide 32: Locations
Locations Midtown East, F17, 410 Teheran- Steinmetz Building Burleigh-on-the-Strand Office 26.01 9-7-2 Akasaka Ro Granta Park, 355-359 Strand Flexoffice Messeturm London 26th Floor Minato-ku GangNam-Gu Cambridge Messeplatz 10 Tokyo 107-0052 Seoul 06192 WC2R 0HS CB21 6DG CH-4058 Basel Japan South Kor
Slide 33: Thank you
Thank you BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS